Free Trial
NASDAQ:CELU

Celularity Q1 2024 Earnings Report

Celularity logo
$1.60 +0.02 (+1.53%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$1.59 -0.01 (-0.56%)
As of 05/2/2025 05:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Celularity EPS Results

Actual EPS
-$1.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Celularity Revenue Results

Actual Revenue
$14.68 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Celularity Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Wednesday, October 16, 2024
Conference Call Time
7:00AM ET

Earnings Documents

Celularity Earnings Headlines

Celularity receives notice regarding non-payment of Nasdaq fees
Elon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to Mars
Elon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech shift. Here’s how to position early.
See More Celularity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celularity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celularity and other key companies, straight to your email.

About Celularity

Celularity (NASDAQ:CELU), a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

View Celularity Profile

More Earnings Resources from MarketBeat